Table 3.
Summary of Best Overall Response
| RECIST 1.1 | mRECIST | |||||
|---|---|---|---|---|---|---|
| Best Response | Atezo/Bev-TACE (n=34) | LEN-TACE (n=34) | P value | Atezo/Bev-TACE (n=34) | LEN-TACE (n=34) | P value |
| Complete response (CR) | 0 (0) | 0 (0) | 4 (11.8) | 4 (11.8) | ||
| Partial response (PR) | 9 (26.5) | 5 (14.7) | 17 (50.0) | 16 (47.1) | ||
| Stable disease (SD) | 17 (50.0) | 24 (70.6) | 7 (20.6) | 9 (26.5) | ||
| Progressive disease (PD) | 8 (23.5) | 5 (14.7) | 6 (17.6) | 5 (14.7) | ||
| ORR (CR+PR) | 9 (26.5) | 5 (14.7) | 0.230 | 21 (61.8) | 20 (58.8) | 0.804 |
| DCR (CR+PR+SD) | 26 (76.5) | 29 (85.3) | 0.355 | 28 (82.4) | 29 (85.3) | 0.742 |
Abbreviations: ORR, objective response rate; DCR, disease control rate; TACE, transarterial chemoembolization; Atezo/Bev, Atezolizumab plus Bevacizumab; LEN, lenvatinib.